Search

Your search keyword '"Piazza, N"' showing total 526 results
Start Over Author "Piazza, N"

Refine your results

more »

more »

more »

more »

more »
526 results on '"Piazza, N"'

1. Human REGENERATIVE MACROPHAGES (REMaST®) CELL THERAPY DEVELOPMENT FOR CLINICAL USE

Author

Bifari, F., primary, Pruonto, G., additional, Sagripanti, L., additional, Barone, I., additional, Amenta, A., additional, Dolci, S., additional, Rossi, E., additional, Mannino, L., additional, Ciarpella, F., additional, Piazza, N., additional, Gianoli, S., additional, Savino, B., additional, Bossolasco, P., additional, Fumagalli, G., additional, Locati, M., additional, and Decimo, I., additional

Published
2024
Full Text
View/download PDF

4. Quantitative aortography for assessment of aortic regurgitation in the era of percutaneous aortic valve replacement.

Author

Abdelshafy, M., Serruys, P.W., Tsai, T.Y., Revaiah, P.C., Garg, S., Aben, J.P., Schultz, C.J., Abdelghani, M., Tonino, P.A.L., Miyazaki, Y., Rutten, M.C.M., Cox, M., Sahyoun, C., Teng, J., Tateishi, H., Abdel-Wahab, M., Piazza, N., Pighi, M., Modolo, R., Mourik, M. van, Wykrzykowska, J., Winter, R.J. de, Lemos, P.A., Brito FS, J.r. de, Kawashima, H., Søndergaard, L., Rosseel, L., Wang, R., Gao, C., Tao, L., Rück, A., Kim, W.K., Royen, N. van, Terkelsen, C.J., Nissen, H., Adam, M., Rudolph, T.K., Wienemann, H., Torii, R., Josef Neuman, F., Schoechlin, S., Chen, M., Elkoumy, A., Elzomor, H., Amat-Santos, I.J., Mylotte, D., Soliman, O., Onuma, Y., Abdelshafy, M., Serruys, P.W., Tsai, T.Y., Revaiah, P.C., Garg, S., Aben, J.P., Schultz, C.J., Abdelghani, M., Tonino, P.A.L., Miyazaki, Y., Rutten, M.C.M., Cox, M., Sahyoun, C., Teng, J., Tateishi, H., Abdel-Wahab, M., Piazza, N., Pighi, M., Modolo, R., Mourik, M. van, Wykrzykowska, J., Winter, R.J. de, Lemos, P.A., Brito FS, J.r. de, Kawashima, H., Søndergaard, L., Rosseel, L., Wang, R., Gao, C., Tao, L., Rück, A., Kim, W.K., Royen, N. van, Terkelsen, C.J., Nissen, H., Adam, M., Rudolph, T.K., Wienemann, H., Torii, R., Josef Neuman, F., Schoechlin, S., Chen, M., Elkoumy, A., Elzomor, H., Amat-Santos, I.J., Mylotte, D., Soliman, O., and Onuma, Y.

Abstract

Contains fulltext : 296015.pdf (Publisher’s version ) (Open Access), Paravalvular leak (PVL) is a shortcoming that can erode the clinical benefits of transcatheter valve replacement (TAVR) and therefore a readily applicable method (aortography) to quantitate PVL objectively and accurately in the interventional suite is appealing to all operators. The ratio between the areas of the time-density curves in the aorta and left ventricular outflow tract (LVOT-AR) defines the regurgitation fraction (RF). This technique has been validated in a mock circulation; a single injection in diastole was further tested in porcine and ovine models. In the clinical setting, LVOT-AR was compared with trans-thoracic and trans-oesophageal echocardiography and cardiac magnetic resonance imaging. LVOT-AR > 17% discriminates mild from moderate aortic regurgitation on echocardiography and confers a poor prognosis in multiple registries, and justifies balloon post-dilatation. The LVOT-AR differentiates the individual performances of many old and novel devices and is being used in ongoing randomized trials and registries.

Published
2023

11. Breast cancer screening adhesion among migrants: a matter of communication strategy?

Author

Banzola, S, Corsaro, A, Capitani, S, Vesco, S, Dodi, L, Serra, O, Piazza, N, Onesti, S, Salvati, M, Musolino, A, Salvati, MA, Banzola, S, Corsaro, A, Capitani, S, Vesco, S, Dodi, L, Serra, O, Piazza, N, Onesti, S, Salvati, M, Musolino, A, and Salvati, MA

Abstract

Background Migrants’ engagement to cancer screening programs is a relevant issue for universalistic health systems. To increase breast cancer screening coverage among migrant women, a public-private partnership involving a multidisciplinary team of Primary Care, Public Health, Hospital and private social workers has been built up in a district in Italy. The team worked in two steps, planning health promotion (HP) meetings addressing women in refugees’ reception programs and a web-based workshop involving intercultural mediators (IMs) and community health promoters. Objectives The workshop, involving 10 professionals among IMs and community health promoters, realized in 3 online meetings during March ‘22, aimed at identifying communication tools to enable migrants’ participation to breast cancer screening and increasing health literacy (HL) and cultural competence (CC) among the team. A participatory approach, supported by learning methods, such as storytelling and role-play, has been adopted to identify the major barriers to access to screening and public health messages. Participants worked on critical words and concepts, highlighted during HP meetings, accounting for HL, literacy, language skills, communication techniques and different perspectives about health and prevention. Results Several barriers, such as lack of knowledge on preventive initiatives and different approaches to health, decrease the perception of cancer risk. Others, like family and work duties, influence the adhesion. Fear or shame about the exam and linguistic issues are further hampering factors. Participants pointed out text, audio and video messages, in Italian and native plain language, as useful tools to explain the screening procedure and give relevant and practical information supported by simple and clear illustrations to diffuse via WhatsApp. Conclusions The intervention enabled the team to improve HL and CC defining suitable communication strategies for cancer screening programs.

Published
2022

12. Generation of hippocampal organoids: a developmental study

Author

Ciarpella, F, Zamfir, R, Campanelli, A, Ren, E, Pedrotti, G, Bottani, E, Caron, D, Di Chio, M, Dolci, S, Ahtiainen, A, Piazza, N, Malpeli, G, Malerba, G, Bardoni, R, Fumagalli, Gf, Hyttinen, Ja, Bifari, F, Palazzolo, G, Panuccio, G, Curia, G, and Decimo, I

Published
2022

13. Predictors of Outcomes Following Transcatheter Edge-to-Edge Mitral Valve Repair

Author

Ben-Shoshan J, Overtchook P, Buithieu J, Mousavi N, Martucci G, Spaziano M, de Varennes B, Lachapelle K, Brophy J, Modine T, Baumbach A, Maisano F, Prendergast B, Tamburino C, Windecker S, Piazza N, Ben-Shoshan, J, Overtchook, P, Buithieu, J, Mousavi, N, Martucci, G, Spaziano, M, de Varennes, B, Lachapelle, K, Brophy, J, Modine, T, Baumbach, A, Maisano, F, Prendergast, B, Tamburino, C, Windecker, S, and Piazza, N

Published
2020

16. Valve Academic Research Consortium 3

Author

Genereux, P., Piazza, N., Alu, M.C., Nazif, T., Hahn, R.T., Pibarot, P., Bax, J.J., Leipsic, J.A., Blanke, P., Blackstone, E.H., Finn, M.T., Kapadia, S., Linke, A., Mack, M.J., Makkar, R., Mehran, R., Popma, J.J., Reardon, M., Rodes-Cabau, J., Mieghem, N.M. van, Webb, J.G., Cohen, D.J., Leon, M.B., VARC-3 Writing Comm, and Cardiology

Subjects
Aortic valve, medicine.medical_specialty, endpoints, Definitions, 030204 cardiovascular system & hematology, 03 medical and health sciences, Quality of life (healthcare), 0302 clinical medicine, Aortic valve replacement, KEY WORDS definitions, Clinical endpoint, Medicine, Clinical significance, 030212 general & internal medicine, Data reporting, Intensive care medicine, transcatheter aortic valve implantation, Valve Academic Research Consortium, Surrogate endpoint, business.industry, medicine.disease, Clinical trial, Clinical research, medicine.anatomical_structure, transcatheter aortic valve replacement, Professional association, Thickening, Cardiology and Cardiovascular Medicine, business, surgical aortic valve replacement
Abstract

Aims The Valve Academic Research Consortium (VARC), founded in 2010, was intended to (i) identify appropriate clinical endpoints and (ii) standardize definitions of these endpoints for transcatheter and surgical aortic valve clinical trials. Rapid evolution of the field, including the emergence of new complications, expanding clinical indications, and novel therapy strategies have mandated further refinement and expansion of these definitions to ensure clinical relevance. This document provides an update of the most appropriate clinical endpoint definitions to be used in the conduct of transcatheter and surgical aortic valve clinical research. Methods and results Several years after the publication of the VARC-2 manuscript, an in-person meeting was held involving over 50 independent clinical experts representing several professional societies, academic research organizations, the US Food and Drug Administration (FDA), and industry representatives to (i) evaluate utilization of VARC endpoint definitions in clinical research, (ii) discuss the scope of this focused update, and (iii) review and revise specific clinical endpoint definitions. A writing committee of independent experts was convened and subsequently met to further address outstanding issues. There were ongoing discussions with FDA and many experts to develop a new classification schema for bioprosthetic valve dysfunction and failure. Overall, this multi-disciplinary process has resulted in important recommendations for data reporting, clinical research methods, and updated endpoint definitions. New definitions or modifications of existing definitions are being proposed for repeat hospitalizations, access site-related complications, bleeding events, conduction disturbances, cardiac structural complications, and bioprosthetic valve dysfunction and failure (including valve leaflet thickening and thrombosis). A more granular 5-class grading scheme for paravalvular regurgitation (PVR) is being proposed to help refine the assessment of PVR. Finally, more specific recommendations on quality-of-life assessments have been included, which have been targeted to specific clinical study designs. Conclusions Acknowledging the dynamic and evolving nature of less-invasive aortic valve therapies, further refinements of clinical research processes are required. The adoption of these updated and newly proposed VARC-3 endpoints and definitions will ensure homogenous event reporting, accurate adjudication, and appropriate comparisons of clinical research studies involving devices and new therapeutic strategies.

Published
2021

17. Neo-LVOT and Transcatheter Mitral Valve Replacement Expert Recommendations

Author

Reid, A., Zekry, S. ben, Turaga, M., Tarazi, S., Bax, J.J., Wang, D.D., Piazza, N., Bapat, V.N., Ihdayhid, A.R., Cavalcante, J.L., Blanke, P., and Leipsic, J.

Subjects
neo-LVOT, transcatheter mitral valve replacement, LVOT obstruction, LVOT
Abstract

With the advent of transcatheter mitral valve replacement (TMVR), the concept of the neo-left ventricular outflow tract (LVOT) was introduced and remains an essential component of treatment planning. This paper describes the LVOT anatomy and provides a step-by-step computed tomography methodology to segment and measure the neo-LVOT while discussing the current evidence and outstanding challenges. It also discusses the technical and hemodynamic factors that play a major role in assessing the neo-LVOT. A summary of expert-based recommendations about the overall risk of LVOT obstruction in different scenarios is presented along with the currently available methods to reduce the risk of LVOT obstruction and other post-procedural complications. (C) 2021 by the American College of Cardiology Foundation.

Published
2021

19. Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV 2 infection: an IG-IBD study

Author

Bezzio, C., Armuzzi, A., Furfaro, F., Ardizzone, S., Milla, M., Carparelli, S., Orlando, A., Caprioli, F. A., Castiglione, F., Vigano, C., Ribaldone, D. G., Zingone, F., Monterubbianesi, R., Imperatore, N., Festa, S., Daperno, M., Scucchi, L., Ferronato, A., Pastorelli, L., Balestrieri, P., Ricci, C., Cappello, M., Felice, C., Fiorino, G., Saibeni, S., Coppini, F., Alvisi, P., Gerardi, V., Variola, A., Mazzuoli, S., Lenti, M. V., Pugliese, D., Allocca, M., Ferretti, F., Roselli, J., Bossa, F., Giuliano, A., Piazza, N., Manes, G., Sartini, A., Buda, A., Micheli, F., Ciardo, V., Casella, G., Viscido, A., Bodini, G., Casini, V., Soriano, A., Amato, A., Grossi, L., Onali, S., Rottoli, M., Spagnuolo, R., Baroni, S., Cortelezzi, C. C., Baldoni, M., Vernero, M., Scaldaferri, F., Maconi, G., Guarino, A. D., Palermo, A., D'Inca, R., Scribano, M. L., Biancone, L., Carrozza, L., Ascolani, M., Costa, F., Di Sabatino, A., Zammarchi, I., Gottin, M., Conforti, F. S., Bezzio, Cristina, Armuzzi, Alessandro, Furfaro, Federica, Ardizzone, Sandro, Milla, Monica, Carparelli, Sonia, Orlando, Ambrogio, Caprioli, Flavio Andrea, Castiglione, Fabiana, Viganò, Chiara, Ribaldone, Davide Giuseppe, Zingone, Fabiana, Monterubbianesi, Rita, Imperatore, Nicola, Festa, Stefano, Daperno, Marco, Scucchi, Ludovica, Ferronato, Antonio, Pastorelli, Luca, Balestrieri, Paola, Ricci, Chiara, Cappello, Maria, Felice, Carla, Fiorino, Gionata, Saibeni, Simone, and Francesca Coppini, Patrizia Alvisi, Viviana Gerardi, Angela Variola, Silvia Mazzuoli, Marco Vincenzo Lenti, Daniela Pugliese, Mariangela Allocca, Francesca Ferretti, Jenny Roselli, Fabrizio Bossa, Alessandra Giuliano, Nicole Piazza, Gianpiero Manes, Alessandro Sartini, Andrea Buda, Federica Micheli, Valeria Ciardo, Giovanni Casella, Angelo Viscido, Giorgia Bodini, Valentina Casini, Alessandra Soriano, Arnaldo Amato, Laurino Grossi, Sara Onali, Matteo Rottoli, Rocco Spagnuolo, Stefania Baroni, Claudio Cortelezzi, Monia Baldoni, Marta Vernero, Franco Scaldaferri, Giovanni Maconi, Alessia Dalila Guarino, Andrea Palermo, Renata D'Incà, Maria Lia Scribano, Livia Biancone, Lucio Carrozza, Marta Ascolani, Francesco Costa, Antonio Di Sabatino, Irene Zammarchi, Matteo Gottin, Francesco Simone Conforti

Subjects
medicine.medical_specialty, Settore MED/12 - GASTROENTEROLOGIA, IBD, Population, Ulcerative, Disease, Lower risk, Asymptomatic, Inflammatory bowel disease, Aged, Humans, SARS-CoV-2, Tumor Necrosis Factor Inhibitors, COVID-19, Colitis, Ulcerative, Crohn Disease, Inflammatory Bowel Diseases, IBD Treatments and Sars‐cov‐2 Infection, Internal medicine, medicine, biologics, Pharmacology (medical), education, therapy, education.field_of_study, Hepatology, business.industry, INFLAMMATORY BOWEL DISEASE, Gastroenterology, medicine.disease, Colitis, Ulcerative colitis, Pneumonia, Original Article, medicine.symptom, business, Cohort study
Abstract

Summary Background Older age and comorbidities are the main risk factors for adverse COVID‐19 outcomes in patients with inflammatory bowel disease (IBD). The impact of IBD medications is still under investigation. Aims To assess risk factors for adverse outcomes of COVID‐19 in IBD patients and use the identified risk factors to build risk indices. Methods Observational cohort study. Univariable and multivariable logistic regression was used to identify risk factors associated with pneumonia, hospitalisation, need for ventilatory support, and death. Results Of the 937 patients (446 with ulcerative colitis [UC]) evaluated, 128 (13.7%) had asymptomatic SARS‐CoV‐2 infection, 664 (70.8%) had a favourable course, and 135 (15.5%) had moderate or severe COVID‐19. In UC patients, obesity, active disease and comorbidities were significantly associated with adverse outcomes. In patients with Crohn's disease (CD), age, obesity, comorbidities and an additional immune‐mediated inflammatory disease were identified as risk factors. These risk factors were incorporated into two indices to identify patients with UC or CD with a higher risk of adverse COVID‐19 outcomes. In multivariable analyses, no single IBD medication was associated with poor COVID‐19 outcomes, but anti‐TNF agents were associated with a lower risk of pneumonia in UC, and lower risks of hospitalisation and severe COVID‐19 in CD. Conclusion The course of COVID‐19 in patients with IBD is similar to that in the general population. IBD patients with active disease and comorbidities are at greater risk of adverse COVID‐19 outcomes. IBD medications do not pose additional risks. The risk indices may help to identify patients who should be prioritised for COVID‐19 re‐vaccination or for therapies for SARS‐CoV‐2 infection., The course of COVID‐19 in patients with IBD patients is similar to that in the general population. IBD patients with active disease and comorbidities are at greater risk of adverse COVID‐19 outcomes. IBD medications do not pose additional risks.

Published
2021

20. Risk of COVID 19 in patients with inflammatory bowel diseases compared to a control population.

Author

Ardizzone S., Saibeni S., Alicante S., Ferretti F., Rizzardini G., Galli M., Maconi G., Bosetti C., De Monti A., Boyapati R.K., Shelton E., Piazza N., Carvalhas Gabrielli A.M., Lenti M.V., Bezzio C., Ricci C., Greco S., Romeo S., Giangregorio F., Gridavilla D., Tagliani F., Massari A., Pastorelli L., Di Sabatino A., Ardizzone S., Saibeni S., Alicante S., Ferretti F., Rizzardini G., Galli M., Maconi G., Bosetti C., De Monti A., Boyapati R.K., Shelton E., Piazza N., Carvalhas Gabrielli A.M., Lenti M.V., Bezzio C., Ricci C., Greco S., Romeo S., Giangregorio F., Gridavilla D., Tagliani F., Massari A., Pastorelli L., and Di Sabatino A.

Abstract

Background: It is unclear whether patients with inflammatory bowel disease (IBD) are at increased risk of COVID-19. Objective(s): This observational study compared the prevalence of COVID-19 symptoms, diagnosis and hospitalization in IBD patients with a control population with non-inflammatory bowel disorders. Method(s): This multicentre study, included 2733 outpatients (1397 IBD patients and 1336 controls), from eight major gastrointestinal centres in Lombardy, Italy. Patients were invited to complete a web-based questionnaire regarding demographic, historical and clinical features over the previous 6 weeks. The prevalence of COVID-19 symptoms, diagnosis and hospitalization for COVID-19 was assessed. Result(s): 1810 patients (64%) responded to the questionnaire (941 IBD patients and 869 controls). IBD patients were significantly younger and of male sex than controls. NSAID use and smoking were more frequent in controls. IBD patients were more likely treated with vitamin-D and vaccinated for influenza. Highly probable COVID-19 on the basis of symptoms and signs was less frequent in the IBD group (3.8% vs 6.3%; OR:0.45, 95%CI:0.28-0.75). IBD patients had a lower rate of nasopharyngeal swab-PCR confirmed diagnosis (0.2% vs 1.2%; OR:0.14, 95%CI:0.03-0.67). There was no difference in hospitalization between the groups (0.1% vs 0.6%; OR:0.14, 95%CI:0.02-1.17). Conclusion(s): IBD patients do not have an increased risk of COVID-19 specific symptoms or more severe disease compared with a control group of gastroenterology patients.Copyright © 2021 Editrice Gastroenterologica Italiana S.r.l.

Published
2021

21. Transcatheter Replacement of Transcatheter Versus Surgically Implanted Aortic Valve Bioprostheses

Author

Landes, U, Sathananthan, J, Witberg, G, de Backer, O, Sondergaard, L, Abdel-Wahab, M, Holzhey, D, Kim, WK, Hamm, C, Buzzatti, N, Montorfano, M, Ludwig, S, Conradi, L, Seiffert, M, Guerrero, M, El Sabbagh, A, Rodés-Cabau, J, Guimaraes, L, Codner, P, Okuno, T, Pilgrim, T, Fiorina, C, Colombo, A, Mangieri, A, Eltchaninoff, H, Nombela-Franco, L, van Wiechen, Maarten, van Mieghem, Nicolas, Tchétché, D, Schoels, WH, Kullmer, M, Tamburino, C, Sinning, JM, Al-Kassou, B, Perlman, GY, Danenberg, H, Ielasi, A, Fraccaro, C, Tarantini, G, De Marco, F, Redwood, SR, Lisko, JC, Babaliaros, VC, Laine, M, Nerla, R, Castriota, F, Finkelstein, A, Loewenstein, I, Eitan, A, Jaffe, R, Ruile, P, Neumann, FJ, Piazza, N, Alosaimi, H, Sievert, H, Sievert, K, Russo, M, Andreas, M, Bunc, M, Latib, A, Godfrey, R, Hildick-Smith, D, Chuang, MYA, Blanke, P, Leipsic, J, Wood, DA, Nazif, T M, Kodali, S, Barbanti, M, Kornowski, R, Leon, MB, Webb, JG, Landes, U, Sathananthan, J, Witberg, G, de Backer, O, Sondergaard, L, Abdel-Wahab, M, Holzhey, D, Kim, WK, Hamm, C, Buzzatti, N, Montorfano, M, Ludwig, S, Conradi, L, Seiffert, M, Guerrero, M, El Sabbagh, A, Rodés-Cabau, J, Guimaraes, L, Codner, P, Okuno, T, Pilgrim, T, Fiorina, C, Colombo, A, Mangieri, A, Eltchaninoff, H, Nombela-Franco, L, van Wiechen, Maarten, van Mieghem, Nicolas, Tchétché, D, Schoels, WH, Kullmer, M, Tamburino, C, Sinning, JM, Al-Kassou, B, Perlman, GY, Danenberg, H, Ielasi, A, Fraccaro, C, Tarantini, G, De Marco, F, Redwood, SR, Lisko, JC, Babaliaros, VC, Laine, M, Nerla, R, Castriota, F, Finkelstein, A, Loewenstein, I, Eitan, A, Jaffe, R, Ruile, P, Neumann, FJ, Piazza, N, Alosaimi, H, Sievert, H, Sievert, K, Russo, M, Andreas, M, Bunc, M, Latib, A, Godfrey, R, Hildick-Smith, D, Chuang, MYA, Blanke, P, Leipsic, J, Wood, DA, Nazif, T M, Kodali, S, Barbanti, M, Kornowski, R, Leon, MB, and Webb, JG

Abstract

Background: Surgical aortic valve replacement and transcatheter aortic valve replacement (TAVR) are now both used to treat aortic stenosis in patients in whom life expectancy may exceed valve durability. The choice of initial bioprosthesis should therefore consider the relative safety and efficacy of potential subsequent interventions. Objectives: The aim of this study was to compare TAVR in failed transcatheter aortic valves (TAVs) versus surgical aortic valves (SAVs). Methods: Data were collected on 434 TAV-in-TAV and 624 TAV-in-SAV consecutive procedures performed at centers participating in the Redo-TAVR international registry. Propensity score matching was applied, and 330 matched (165:165) patients were analyzed. Principal endpoints were procedural success, procedural safety, and mortality at 30 days and 1 year. Results: For TAV-in-TAV versus TAV-in-SAV, procedural success was observed in 120 (72.7%) versus 103 (62.4%) patients (p = 0.045), driven by a numerically lower frequency of residual high valve gradient (p = 0.095), ectopic valve deployment (p = 0.081), coronary obstruction (p = 0.091), and conversion to open heart surgery (p = 0.082). Procedural safety was achieved in 116 (70.3%) versus 119 (72.1%) patients (p = 0.715). Mortality at 30 days was 5 (3%) after TAV-in-TAV and 7 (4.4%) after TAV-in-SAV (p = 0.570). At 1 year, mortality was 12 (11.9%) and 10 (10.2%), respectively (p = 0.633). Aortic valve area was larger (1.55 ± 0.5 cm2 vs. 1.37 ± 0.5 cm2; p = 0.040), and the mean residual gradient was lower (12.6 ± 5.2 mm Hg vs. 14.9 ± 5.2 mm Hg; p = 0.011) after TAV-in-TAV. The rate of moderate or greater residual aortic regurgitation was similar, but mild aortic regurgitation was more frequent after TAV-in-TAV (p = 0.003). Conclusions: In propensity score–matched cohorts of TAV-in-TAV versus TAV-in-SAV patients, TAV-in-TAV was associated with higher procedural success and similar procedural safety or mortality.

Published
2021

22. Transcatheter mitral valve implantation

Author

Taramasso M, Russo G, Guidotti A, Moat N, Cheung A, Imbert D, Duncan A, Watson AJ, Piazza N, Maisano F, Naber C, Baumbach A, Vahanian A, Taramasso, M, Russo, G, Guidotti, A, Moat, N, Cheung, A, Imbert, D, Duncan, A, Watson, Aj, Piazza, N, and Maisano, F

Published
2019

23. Transcatheter Treatment of Residual Significant Mitral Regurgitation Following TAVR: A Multicenter Registry

Author

Witberg, G, Codner, P, Landes, U, Brabanti, M, Valvo, R, De Backer, O, Ooms, JF, Sievert, K, El Sabbagh, A, Jimenez-Quevedo, P, Brennan, PF, Sedaghat, A, Masiero, G, Werner, P, Overtchouk, P, Watanabe, Y, Montorfano, M, Bijjam, VR, Hein, M, Fiorina, C, Arzamendi, D, Rodriguez-Gabella, T, Fernandez-Vazquez, F, Baz, JA, Laperche, C, Grasso, C, Branca, L, Estevez-Loureiro, R, Benito-Gonzalez, T, Santos, IJA, Ruile, P, Mylotte, D, Buzzatti, N, Piazza, N, Andreas, M, Tarantini, G, Sinning, JM, Spence, MS, Nombela-Franco, L, Guerrero, M, Sievert, H, Sondergaard, L, Van Mieghem, NM, Tchetche, D, Webb, JG, Kornowski, R, and Cardiology

Subjects
Aged, 80 and over, Mitral Valve Insufficiency, aortic stenosis, Aortic Valve Stenosis, TAVR, Severity of Illness Index, mitral regurgitation, TMVR/r, Transcatheter Aortic Valve Replacement, Treatment Outcome, Aortic Valve, Humans, Registries, Aged
Abstract

OBJECTIVES The aim of this study was to describe baseline characteristics, and periprocedural and mid-term outcomes of patients undergoing transcatheter mitral valve interventions post-transcatheter aortic valve replacement (TAVR) and examine their clinical benefit. BACKGROUND The optimal management of residual mitral regurgitation (MR) post-TAVR is challenging. METHODS This was an international registry of 23 TAVR centers. RESULTS In total, 106 of 24,178 patients (0.43%) underwent mitral interventions post-TAVR (100 staged, 6 concomitant), most commonly percutaneous edge-to-edge mitral valve repair (PMVR). The median interval post-TAVR was 164 days. Mean age was 79.5 +/- 7.2 years, MR was >moderate in 97.2%, technical success was 99.1%, and 30-day device success rate was 88.7%. There were 18 periprocedural complications (16.9%) including 4 deaths. During a median follow-up of 464 days, the cumulative risk for 3-year mortality was 29.0%. MR grade and New York Heart Association (NYHA) functional class improved dramatically; at 1 year, MR was moderate or less in 90.9% of patients (mild or less in 69.1%), and 85.9% of patients were in NYHA functional class I/II. Staged PMVR was associated with lower mortality versus medical treatment (57.5% vs. 30.8%) in a propensity-matched cohort (n = 156), but this was not statistically significant (hazard ratio: 1.75; p = 0.05). CONCLUSIONS For patients who continue to have significant MR, remain symptomatic post-TAVR, and are anatomically suitable for transcatheter interventions, these interventions are feasible, safe, and associated with significant improvement in MR grade and NYHA functional class. These results apply mainly to PMVR. A staged PMVR strategy was associated with markedly lower mortality, but this was not statistically significant. (Transcatheter Treatment for Combined Aortic and Mitral Valve Disease. The Aortic+Mitral TRAnsCatheter Valve Registry [AMTRAC]; NCT04031274) (C) 2020 by the American College of Cardiology Foundation.

Published
2020

24. Quantitative Assessment of Acute Regurgitation Following TAVR A Multicenter Pooled Analysis of 2,258 Valves

Author

Modolo, R, Chang, Chun-Chin, Abdelghani, M, Kawashima, H, Ono, M, Tateishi, Hiroki, Miyazaki, Yosuke, Pighi, M, Wykrzykowska, JJ, de Winter, RJ, Ruck, A, Chieffo, A, van Mourik, MS, Yamaji, K, de Brito, FS, Lemos, PA, Al-Kassou, B, Piazza, N, Tchetche, D, Sinning, JM, Abdel-Wahab, M, Soliman, OII, Sondergaard, L, Mylotte, Darren, Onuma, Y, van Mieghem, Nicolas, Serruys, PWJC, and Cardiology

Published
2020

25. Chimney Stenting for Coronary Occlusion During TAVR: Insights From the Chimney Registry

Author

Mercanti, F, Rosseel, L, Neylon, A, Bagur, R, Sinning, Jm, Nickenig, G, Grube, E, Hildick-Smith, D, Tavano, D, Wolf, A, Colonna, G, Latib, A, Mitomo, S, Petronio, As, Angelillis, M, Tchétché, D, De Biase, C, Adamo, M, Nejjari, M, Digne, F, Schäfer, U, Amabile, N, Achkouty, G, Makkar, Rr, Yoon, Sh, Finkelstein, A, Dvir, D, Jones, T, Chevalier, B, Lefevre, T, Piazza, N, and Mylotte, D.

Subjects
Male, Time Factors, chimney stenting, Prosthesis Design, Coronary Restenosis, Transcatheter Aortic Valve Replacement, Middle East, Percutaneous Coronary Intervention, Risk Factors, 80 and over, Humans, Hospital Mortality, Registries, coronary artery obstruction, coronary protection, myocardial infarction, transcatheter aortic valve replacement, Aged, Aged, 80 and over, Aortic Valve, Coronary Occlusion, Coronary Thrombosis, Europe, Female, North America, Retrospective Studies, Treatment Outcome, Heart Valve Prosthesis, Stents
Abstract

The aim of this study was to determine the safety and efficacy of chimney stenting, a bailout technique to treat coronary artery occlusion (CAO).CAO during transcatheter aortic valve replacement (TAVR) is a rare but often fatal complication.In the international Chimney Registry, patient and procedural characteristics and data on outcomes are retrospectively collected from patients who underwent chimney stenting during TAVR.To date, 16 centers have contributed 60 cases among 12,800 TAVR procedures (0.5%). Chimney stenting was performed for 2 reasons: 1) due to the development of an established CAO (n = 25 [41.6%]); or 2) due to an impending CAO (n = 35 [58.3%]). The majority of cases (92.9%) had 1 or more classical risk factors for CAO. Upfront coronary protection was performed in 44 patients (73.3%). Procedural and in-hospital mortality occurred in 1 and 2 patients, respectively. Myocardial infarction (52.0% vs. 0.0%; p 0.01), cardiogenic shock (52.0% vs. 2.9%; p 0.01), and resuscitation (44.0% vs. 2.9%; p 0.01) all occurred more frequently in patients with established CAO compared with those with impending CAO. The absence of upfront coronary protection was the sole independent risk factor for the combined endpoint of death, cardiogenic shock, or myocardial infarction. During a median follow-up time of 612 days (interquartile range: 405 to 842 days), 2 cases of stent failure were reported (1 in-stent restenosis, 1 possible late stent thrombosis) after 157 and 374 days.Chimney stenting appears to be an acceptable bailout technique for CAO, with higher event rates among those with established CAO and among those without upfront coronary protection.

Published
2020

26. Advances in transcatheter mitral and tricuspid therapies

Author

Overtchouk, P. (Pavel), Piazza, N. (Nicolo), Granada, J.F. (Juan), Soliman, O.I.I. (Osama Ibrahim Ibrahim), Prendergast, P.J. (Patrick), Modine, T. (Thomas), Overtchouk, P. (Pavel), Piazza, N. (Nicolo), Granada, J.F. (Juan), Soliman, O.I.I. (Osama Ibrahim Ibrahim), Prendergast, P.J. (Patrick), and Modine, T. (Thomas)

Abstract

BACKGROUND: While rheumatic mitral stenosis has been effectively treated percutaneously for more than 20 years, mitral and tricuspid regurgitation treatment appear as a contemporary unmet need. The advent of transcatheter therapies offer new treatment options to often elderly and frail patients at high risk for open surgery. We aimed at providing an updated review of fast-growing domain of transcatheter mitral and tricuspid technology. MAIN BODY: We reviewed the existing literature on mitral and tricuspid transcatheter therapies. Mitraclip is becoming an established therapy for secondary mitral regurgitation in selected patients with disproportionately severe regurgitation associated with moderate left ventricle dysfunction. Evidence is less convincing for primary mitral regurgitation. Transcatheter mitral valve replacement is a promising emerging alternative to transcatheter repair, for secondary as well as primary mitral regurgitation. But further development is needed to improve delivery. Transcatheter tricuspid intervention arrives late after similar technologies have been developed for aortic and mitral valves and is currently at its infancy. This is likely due in part to previously under-recognized impact of tricuspid regurgitation on patient outcomes. Edge-to-edge repair is the most advanced transcatheter solution in development. Data on tricuspid annuloplasty and replacement is limited, and more research is warranted. CONCLUSION: The future appears bright for transcatheter mitral therapies, albeit their place in clinical practice is yet to be clearly defined. Tricuspid transcatheter therapies might address the unmet need of tricuspid regurgitation treatment.

Published
2020
Full Text
View/download PDF

30. HANDGRIP STRENGTH PREDICTS MORTALITY IN OLDER ADULTS UNDERGOING CARDIAC SURGERY

Author

Fountotos, R., primary, Munir, H., additional, Goldfarb, M., additional, Moss, E., additional, Perrault, L., additional, Kim, D., additional, Bendayan, M., additional, Piankova, P., additional, Hayman, V., additional, Rodighiero, J., additional, Ouimet, M., additional, Dion, C., additional, Rudski, L., additional, Piazza, N., additional, de Varennes, B., additional, Lachapelle, K., additional, and Afilalo, J., additional

Published
2020
Full Text
View/download PDF

34. Diagnostic and therapeutic workup of erectile dysfunction: results from a delphi consensus of andrology experts

Author

Isidori, A. M., Giammusso, B., Corona, G., Verze, P., Albanesi, L., Antomarchi, F., Arcaniolo, D., Balercia, G., Barbonetti, A., Barletta, D., Barrese, F., Bellastella, G., Biggio, A., Bitelli, M., Botturi, A., Brancato, T., Branchina, A., Cai, T., Canale, D., Capone, L., Capone, M., Carluccini, A., Citarrella, R., Cocci, A., Corvese, F., Cozza, P. P., Creta, M., D'Andrea, S., Dalena, G., Damiano, R., Defeudis, G., Del Grasso, A., Delbarba, A., Delle Rose, A., Di Crosta, G., Filippo, Di, Di Lena, S., Di Martino, M., Di Millo, F., Di Palma, P., Diazzi, D., Dicuio, M., Diosi, D., Fabbri, A., Fattorini, G., Florio, M., Formiconi, A., Franco, G., Galdiero, M., Giambersio, A. M., Gianfrilli, D., Giovannone, R., Granata, A. M., Iafrate, M., Iapicca, G., Iatrino, G., Ilacqua, N., Innocenti, F., Italiano, E., Izzo, A., Izzo, P., Lamartina, M., Ledda, A. F., Lepri, L., C. F., Lo, Lombardo, F., Luca, G., Macchione, L., Maga, T., Matteo, M., Malvestiti, G. M., Marella, G., Maretti, C., Maturo, G., Mazzaferro, D., Mazzilli, R., Migliorini, F., Milardi, D., Minardi, V., Moiso, A., Mondaini, N., Moretti, M., Motta, G., Nerva, F., Pastore, A. L., Paulis, G., Piazza, N., Pili, M., Pistone, A., Pivonello, R., Pizzocaro, A., Polverini, M., Provinzano, V., Rastrelli, G., Risi, O., Rocchegiani, A., Rolle, L., Romanelli, F., Romano, G., Russo, G. I., Salemi, G., Salzano, C., Sanna, F., Sansone, A., Santi, D., Scalese, G. A., Scarano, P., Scroppo, F. I., Serrao, M. F., Sidoti, G., Silvestre, G., Simone, O., Sorrentino, M., Tallis, V., Tammaro, R., Ughi, G., Vagnoni, V., Vavallo, A., Vecchio, D., Vita, A., Zicarelli, P., and Zucchi, A.

Subjects
Consensus, erectile dysfunction, Urology, Endocrinology, Diabetes and Metabolism, media_common.quotation_subject, education, 030232 urology & nephrology, lcsh:Medicine, Dermatology, Delphi, Consensus method, Likert scale, Andrology, 03 medical and health sciences, Behavioral Neuroscience, 0302 clinical medicine, Endocrinology, Erectile Dysfunction, PDE5 Inhibitors, Treatment, Voting, medicine, PDE5 inhibitors, computer.programming_language, media_common, 030219 obstetrics & reproductive medicine, treatment, business.industry, lcsh:R, lcsh:Other systems of medicine, medicine.disease, lcsh:RZ201-999, consensus, delphi, Phosphodiesterase Type 5 Inhibitors, Clinical Practice, Psychiatry and Mental health, Erectile dysfunction, Hot topics, Reproductive Medicine, business, computer
Abstract

Introduction Erectile dysfunction is a highly prevalent condition. Existing guidelines provide recommendations for diagnosis and treatment, but they are often disregarded in clinical practice in favor of a “patient-tailored” approach. Objectives We planned a Delphi consensus method to bridge the gap between evidence-based medicine and the real-life approach in daily practice. Materials and Methods The Advisory Board prepared 15 statements on debated topics in andrology, each including 4–6 items designed as a 5-point Likert scale. After a validation phase, the questionnaire was sent by e-mail to a panel of experts for a first round of voting; members of the panel were later invited to a second round of voting, preceded by discussion of the “hot topics” identified in the first round. Results The first round of the Delphi consensus involved 101 experts; 71 (70%) also took part in the second round of voting. The Advisory Board deemed 22 items to be worthy of debate, and these underwent the second round of voting. “Real-life” results from the survey proved quite different from evidence-based recommendations. Conclusion Although guidelines suggest the best approach for a “standard” patient, real-life settings require flexibility. Diagnostic and therapeutic approaches should be tailored to the patients’ needs. Phosphodiesterase type 5 inhibitors are recognized as the first-line therapy in both settings, including the newly introduced sildenafil orodispersible film. Indications from the panel might help close the gap between recommendations from guidelines and real-life practice in relation to the diagnosis and treatment of erectile dysfunction.

Published
2019

35. Multimodality Imaging of the Tricuspid Valve and Right Heart Anatomy

Author

Khalique, O, Cavalcante, J, Shah, D, Guta, A, Zhan, Y, Piazza, N, Muraru, D, Khalique, Omar K., Cavalcante, João L., Shah, Dipan, Guta, Andrada C., Zhan, Yang, Piazza, Nicolo, Muraru, Denisa, Khalique, O, Cavalcante, J, Shah, D, Guta, A, Zhan, Y, Piazza, N, Muraru, D, Khalique, Omar K., Cavalcante, João L., Shah, Dipan, Guta, Andrada C., Zhan, Yang, Piazza, Nicolo, and Muraru, Denisa

Abstract

The characterization of tricuspid valve and right-heart anatomy has been gaining significant interest in the setting of new percutaneous transcatheter interventions for tricuspid regurgitation. Multimodality cardiac imaging provides a wealth of information about the anatomy and function of the tricuspid valve apparatus, right ventricle, and right atrium, which is pivotal for diagnosis and prognosis and for planning of percutaneous interventions. The present review describes the role of echocardiography, cardiac magnetic resonance, and multidetector row cardiac computed tomography for right heart and tricuspid valve assessment.

Published
2019

36. Transcatheter aortic valve implantation in 2015

Author

Mylotte, D., Sharif, F., Piazza, N., Moscarelli, M., Fattouch, K., Modine, T., Mylotte, D., Sharif, F., Piazza, N., Moscarelli, M., Fattouch, K., and Modine, T

Subjects
Echocardiography, Symposium: Transcatheter aortic valve implantation, Aortic valve, Risk factor, Surgery, Cardiology and Cardiovascular Medicine, Geriatrics and Gerontology
Abstract

Not available

Published
2016

42. Results from a prospective observational study of men with premature ejaculation treated with dapoxetine or alternative care: The PAUSE study

Author

Mirone V, ARCANIOLO, Davide, Rivas D, Bull S, Aquilina JW, Verze P, PAUSE study team Berchart G, Hass M, Ludvik G, Aalto J, Hendolin N, Lukkarinen O, Multanen M, Nurmenniemi V, Piha J, Aheimer C, Alebrahim Dehkordy A, Andreessen R, Aust C, Baer P, Bath V, Baumgrass H, Beck C, Beecken WD, Behre H, Beitzinger M, Belusa A, Bermes UR, Berning T, Bieringer La Roche D, Blasko S, Boehmer S, Borchardt A, Boerner T, Brands F, Braun PM, Braun R, Breu D, Briken P, Brueske T, Bueker R, Buse A, Carius A, Christoph F, Cuno M, Dats E, Degen N, Denil J, Dietrichs K, Domnitz R, Dorn B, Dubiel J, Eckert R, Ehrenberg W, Eichler S, El Khadra S, Engl T, Esser O, Faragallah EA, Farahmandi R, Finke G, Fleig P, Fruehauf E, Gerhardt U, Girke CG, Glauche J, Gleissner J, Gnann R, Gralla O, Grandin A, Grewe W, Gronau E, Gruber S, Grunert S, Guelbeyaz M, Guelden H, Haendel D, Haefele J, Haghighat M, Hahne D, Haschemi Schirazi R, Hecker D, Herzig J, Hettmmer R, Hitschfeld K, Hofmann J, Hohmuth H, Hoelker D, Huebner A, Hudemann B, Hung Wehmann D, Huenninghaus K, Hueter K, Igde H, Jaeger T, Javadi P, John G, Ju M, Kaisser G, Kamann L, Kastein A, Kaup F, Kellner T, Kempe T, Kempter F, Kennerknecht M, Kirschner P, Koenig M, Konert J, Kowalik S, Krieger JU, Kruppa GL, Kube U, Kuehn F, Kuefer R, Kurt T, Kwela M, Laag R, Langen L, Lehmann J, Linder C, Loeber T, Lock UC, Loebenau M, Luberg Sievers G, Luebbe R, Lutz K, Maier S, Maletz C, Mertins B, Meschede E, Meschi MR, Miersch WD, Misera A, Muehlich S, Mueller HW, Mueller D, Muench HC, Nawka P, Othman K, Paiss T, Peter K, Peters T, Petras T, Petrischenko B, Pfund A, Plate H, Ploss HJ, Pohrt U, Pooyeh S, Potempa AJ, Pusinelli WD, Rausch U, Reinhardt F, Rengel U, Rietheimer W, Rinnab L, Rohrmann K, Romahn E, Romitan Baum R, Roessler T, Rudolph R, Rueffer J, Rug M, Rueth J, Ruettgers E, Santiago RB, Schaefer A, Schaefer T, Schaetzle P, Scheunpflug K, Schlicht J, Schmidt P, Schneider J, Schnitzler M, Schonfelder R, Schreier H, Schroeder A, Schulz FM, Schulze M, Schumann M, Seidler A, Seseke S, Siebel Eggeling G, Siebels M, Sinner B, Sippel F, Soballa M, Sommer F, Spielhaupter A, Steffen H, Steinacker M, Stiersdorfer A, Stoehr C, Sturm S, Surrey HW, Swoboda A, Szymula S, Telle J, Uththoff H, Vierneisel C, Vilmar W, Wagner M, Walhoefer F, Warnack W, Weiss J, Weizert P, Wicht A, Wieland J, Willgerodt J, Wilski B, Wilson E, Wipfler G, Wohn HG, Wolf J, Zoehrlaut B, Zuerner T, Angeletti G, Avolio A, Baldassarre R, Balercia G, Balloni F, Barba G, Bartoletti R, Basile Fasolo C, Bassi PF, Beatrici V, Bertozzi MA, Bocciardi AM, Bondavalli C, Bonini F, Bonsanto M, Branchi A, Briganti A, Calabrese M, Calafiore R, Calogero AE, Cantelmo P, Caraceni E, Carbone A, Cardella A, Carini M, Carmignani L, Carmignani G, Carrino M, Caviglia C, Cecchi M, Ceruti C, Chiovato L, Cicalese V, Colpi G, Corinti M, Cormio L, Cova G, Cozzupoli P, Ottavio G, Damiano R, De Ceglie G, De Grande G, De Lisa A, DE SIO, Marco, De Stefani S, Dehò F, Delsignore A, Di Filippo A, Di Lena S, Di Trapani D, Diambrini M, Drei GN, Fabbri A, Fasolis G, Ferone D, Ferrari G, Foresta C, Francavilla S, Gadda F, Galantini A, Galì A, Gentile V, Giammusso B, Giannubilo W, Granata A, Grasso M, Iafrate M, Ilacqua N, Isidori A, Italiano E, Jallous HA, Jannini E, La Pera G, Laganà F, Lauretti S, Leonardi R, Liguori G, Loiero G, Lombardi G, Lombardo F, Lusenti C, Maffucci A, Maggi M, Maio G, Mammana G, Manieri C, Marzotto Caotorta M, Mastroeni F, Mazzilli F, Mazzone L, Minervini M, Mirone VG, Montorsi F, Morelli G, Morrone G, Nicita G, Nicola M, Palmiotto F, Paradiso M, Paulis G, Pavone C, Pescatori ES, Petterle V, Piazza N, Pittaluga P, Piubello G, Polito M, Ponchietti R, Porena M, Rago R, Risi O, Roggia A, Salzano L, Sanseverino R, SASSO, Ferdinando Carlo, Savoca G, Scarano P, Schips L, Serao A, Sforza A, Sidari V, Silvani M, Sinisi A, Sorrentino F, Spera E, Strada G, Tenaglia R, Terrone C, Titta M, Tracia A, Turchi P, Ughi G, Vecchio D, Veneziano IA, Vicini P, Vita A, Vitti P, Volpi R, Zago T, Zenico T, Zito AR, Apolinario M, Carvalho AP, Corte Real J, Matos Cabeca J, Mendes Leal A, Monteiro Pereira N, Palma dos Reis J, Patricio A, Prisco R, Rocha Mendes J, Santos A, Vieira R, Abad Gairín C, Abascal García JM, Adot Zurbano JM, Álvarez de la Red PL, Al Wattar W, Antón Saiz C, Aranda Doncel N, Arrosagaray PM, Arteaga Serrano F, Barberán Soriano J, Bataller Perello V, Beltrán Persiva J, Benejam Gual J, Blanco Díez A, Blasco Casares FJ, Blasco Villalonga M, Blázquez Izquierdo J, Boladeras Sabater J, Borrás JJ, Bouchi Bakrim AR, Bucar Terrades S, Burgués Gasión JP, Busto Castañón L, Caballero JM, Cabello Santamaría F, Cabreja López E, Carrasco Aznar JC, Casasola Chamorro J, Castellanos González L, Cimadevila García A, Closas Capdevila M, Concepción Masip T, Conde C, Conde Santos G, Cortada i. Robert J, Cos Calvet JM, Crespi Martínez F, Cruz N, De la Rosa Khermann M, Delgado Martín JA, Devesa Mújica M, Doganis Peppas C, Domínguez Freire F, Donderis Guastavino C, Duarte Vázquez JJ, El Khoury Yacob R, Escobal Tamayo V, Farré Martí JM, Fernández Fernández A, Fernández Lozano A, Fernández Viñas JA, Fiter Gómez L, Fleitas Asencio E, Frago Valls SM, Galiana Álvarez A, García Bayo I, García Contreras J, García Cruz E, García de Jalón Martín A, García Giralda L, García Marco MA, García Navas R, García Reboll L, Garrido Insúa S, Giner Santamaría C, Gómez Berjón F, Gómez Gil E, Gómez Lanza E, Gómez Pérez L, Gómez Rodríguez A, González Sala JL, González Sala MJ, Gonzalvo Ybarra A, Guerrero Martínez V, Gutiérrez González MA, Gutierrez Mínguez E, Hidalgo Arroyo J, Hmeidan M, Idígora i. Planas X, Jara Rascón J, Jiménez Verdejo J, Lledó García E, Lliteras Arañi M, López Almansa M, López Palacios MÁ, López Tello J, Lorenzo Gómez MF, Luque Gálvez P, Luque López AJ, Mallafré Sala JM, Martí Cebrián JM, Martín Clos J, Martín Huescar A, Martín Morales A, Martín Rodríguez A, Martínez Rodríguez R, Martínez Salamanca JI, Mascarós Balaguer E, Mejide Manresa R, Molero Rodríguez F, Molina Carranza A, Moncada Iribarren I, Montagud Moncho JB, Montesino Semper M, Mosteiro Ponce JA, Mouaffak Tatari N, Navarro Gil JM, Novás Castro S, Ortiz del Corral ML, Ortiz Gamiz A, Osca García JM, Padilla León M, Palomino García A, Pascual Mateo C, Peinado Ibarra F, Pérez Mestre M, Portillo Martín JA, Poyato Galán JM, Prats de Puig J, Prieto Castro R, Puigvert Martínez A, Quintana de la Rosa JL, Ramada Benlloch FJ, Reyes Martínez F, Rigabert M, Ríos Espuny AF, Robles Iniesta A, Rodrigo Aliaga M, Rodríguez Alba JL, Rodríguez Bethencourt F, Rodríguez Jiménez FJ, Rodríguez Leal DA, Rodríguez Rubio F, Rodríguez Tolrá J, Rodríguez Vallejo JM, Romero Otero J, Roselló Barbará M, Rubio Briones J, Ruíz Moriana O, Sampol Company J, San Martín Blanco C, Sánchez Encinas M, Sánchez Sánchez F, Sancho Serrano C, Santandreu Puifros J, Santisteban González M, Santos Ascarza Tabares JL, Sanz Lahoz I, Sapiña Ortola F, Sarquella Geli J, Segarra Tomás J, Soler Fernández J, Tato Rodríguez J, Tesedo Cubedo J, Traid Sender V, Valbuena Álvarez R, Valverde Rubio JM, Varela Salgado M, Vargas Rugeles M, Vilches Cocovi E, Virto Bajo FJ, Andius P, Anker Hansen O, Arver S, Bosson P, Brattberg A, Grenabo L, Hanning J, Hassler L, Paradis AÅ, Wang E., Mirone, Vincenzo, Arcaniolo, Davide, David, Riva, Scott, Bull, Joseph W., Aquilina, Verze, Paolo, Mirone, V, Arcaniolo, D, Rivas, D, Bull, S, Aquilina, JW, Verze, P, Pavone, C, Aquilina, Jw, PAUSE study team Berchart, G, Hass, M, Ludvik, G, Aalto, J, Hendolin, N, Lukkarinen, O, Multanen, M, Nurmenniemi, V, Piha, J, Aheimer, C, Alebrahim Dehkordy, A, Andreessen, R, Aust, C, Baer, P, Bath, V, Baumgrass, H, Beck, C, Beecken, Wd, Behre, H, Beitzinger, M, Belusa, A, Bermes, Ur, Berning, T, Bieringer La Roche, D, Blasko, S, Boehmer, S, Borchardt, A, Boerner, T, Brands, F, Braun, Pm, Braun, R, Breu, D, Briken, P, Brueske, T, Bueker, R, Buse, A, Carius, A, Christoph, F, Cuno, M, Dats, E, Degen, N, Denil, J, Dietrichs, K, Domnitz, R, Dorn, B, Dubiel, J, Eckert, R, Ehrenberg, W, Eichler, S, El Khadra, S, Engl, T, Esser, O, Faragallah, Ea, Farahmandi, R, Finke, G, Fleig, P, Fruehauf, E, Gerhardt, U, Girke, Cg, Glauche, J, Gleissner, J, Gnann, R, Gralla, O, Grandin, A, Grewe, W, Gronau, E, Gruber, S, Grunert, S, Guelbeyaz, M, Guelden, H, Haendel, D, Haefele, J, Haghighat, M, Hahne, D, Haschemi Schirazi, R, Hecker, D, Herzig, J, Hettmmer, R, Hitschfeld, K, Hofmann, J, Hohmuth, H, Hoelker, D, Huebner, A, Hudemann, B, Hung Wehmann, D, Huenninghaus, K, Hueter, K, Igde, H, Jaeger, T, Javadi, P, John, G, Ju, M, Kaisser, G, Kamann, L, Kastein, A, Kaup, F, Kellner, T, Kempe, T, Kempter, F, Kennerknecht, M, Kirschner, P, Koenig, M, Konert, J, Kowalik, S, Krieger, Ju, Kruppa, Gl, Kube, U, Kuehn, F, Kuefer, R, Kurt, T, Kwela, M, Laag, R, Langen, L, Lehmann, J, Linder, C, Loeber, T, Lock, Uc, Loebenau, M, Luberg Sievers, G, Luebbe, R, Lutz, K, Maier, S, Maletz, C, Mertins, B, Meschede, E, Meschi, Mr, Miersch, Wd, Misera, A, Muehlich, S, Mueller, Hw, Mueller, D, Muench, Hc, Nawka, P, Othman, K, Paiss, T, Peter, K, Peters, T, Petras, T, Petrischenko, B, Pfund, A, Plate, H, Ploss, Hj, Pohrt, U, Pooyeh, S, Potempa, Aj, Pusinelli, Wd, Rausch, U, Reinhardt, F, Rengel, U, Rietheimer, W, Rinnab, L, Rohrmann, K, Romahn, E, Romitan Baum, R, Roessler, T, Rudolph, R, Rueffer, J, Rug, M, Rueth, J, Ruettgers, E, Santiago, Rb, Schaefer, A, Schaefer, T, Schaetzle, P, Scheunpflug, K, Schlicht, J, Schmidt, P, Schneider, J, Schnitzler, M, Schonfelder, R, Schreier, H, Schroeder, A, Schulz, Fm, Schulze, M, Schumann, M, Seidler, A, Seseke, S, Siebel Eggeling, G, Siebels, M, Sinner, B, Sippel, F, Soballa, M, Sommer, F, Spielhaupter, A, Steffen, H, Steinacker, M, Stiersdorfer, A, Stoehr, C, Sturm, S, Surrey, Hw, Swoboda, A, Szymula, S, Telle, J, Uththoff, H, Vierneisel, C, Vilmar, W, Wagner, M, Walhoefer, F, Warnack, W, Weiss, J, Weizert, P, Wicht, A, Wieland, J, Willgerodt, J, Wilski, B, Wilson, E, Wipfler, G, Wohn, Hg, Wolf, J, Zoehrlaut, B, Zuerner, T, Angeletti, G, Avolio, A, Baldassarre, R, Balercia, G, Balloni, F, Barba, G, Bartoletti, R, Basile Fasolo, C, Bassi, Pf, Beatrici, V, Bertozzi, Ma, Bocciardi, Am, Bondavalli, C, Bonini, F, Bonsanto, M, Branchi, A, Briganti, A, Calabrese, M, Calafiore, R, Calogero, Ae, Cantelmo, P, Caraceni, E, Carbone, A, Cardella, A, Carini, M, Carmignani, L, Carmignani, G, Carrino, M, Caviglia, C, Cecchi, M, Ceruti, C, Chiovato, L, Cicalese, V, Colpi, G, Corinti, M, Cormio, L, Cova, G, Cozzupoli, P, Ottavio, G, Damiano, R, De Ceglie, G, De Grande, G, De Lisa, A, DE SIO, Marco, De Stefani, S, Dehò, F, Delsignore, A, Di Filippo, A, Di Lena, S, Di Trapani, D, Diambrini, M, Drei, Gn, Fabbri, A, Fasolis, G, Ferone, D, Ferrari, G, Foresta, C, Francavilla, S, Gadda, F, Galantini, A, Galì, A, Gentile, V, Giammusso, B, Giannubilo, W, Granata, A, Grasso, M, Iafrate, M, Ilacqua, N, Isidori, A, Italiano, E, Jallous, Ha, Jannini, E, La Pera, G, Laganà, F, Lauretti, S, Leonardi, R, Liguori, G, Loiero, G, Lombardi, G, Lombardo, F, Lusenti, C, Maffucci, A, Maggi, M, Maio, G, Mammana, G, Manieri, C, Marzotto Caotorta, M, Mastroeni, F, Mazzilli, F, Mazzone, L, Minervini, M, Mirone, Vg, Montorsi, F, Morelli, G, Morrone, G, Nicita, G, Nicola, M, Palmiotto, F, Paradiso, M, Paulis, G, Pescatori, E, Petterle, V, Piazza, N, Pittaluga, P, Piubello, G, Polito, M, Ponchietti, R, Porena, M, Rago, R, Risi, O, Roggia, A, Salzano, L, Sanseverino, R, Sasso, Ferdinando Carlo, Savoca, G, Scarano, P, Schips, L, Serao, A, Sforza, A, Sidari, V, Silvani, M, Sinisi, A, Sorrentino, F, Spera, E, Strada, G, Tenaglia, R, Terrone, C, Titta, M, Tracia, A, Turchi, P, Ughi, G, Vecchio, D, Veneziano, Ia, Vicini, P, Vita, A, Vitti, P, Volpi, R, Zago, T, Zenico, T, Zito, Ar, Apolinario, M, Carvalho, Ap, Corte Real, J, Matos Cabeca, J, Mendes Leal, A, Monteiro Pereira, N, Palma dos Reis, J, Patricio, A, Prisco, R, Rocha Mendes, J, Santos, A, Vieira, R, Abad Gairín, C, Abascal García, Jm, Adot Zurbano, Jm, Álvarez de la Red, Pl, Al Wattar, W, Antón Saiz, C, Aranda Doncel, N, Arrosagaray, Pm, Arteaga Serrano, F, Barberán Soriano, J, Bataller Perello, V, Beltrán Persiva, J, Benejam Gual, J, Blanco Díez, A, Blasco Casares, Fj, Blasco Villalonga, M, Blázquez Izquierdo, J, Boladeras Sabater, J, Borrás, Jj, Bouchi Bakrim, Ar, Bucar Terrades, S, Burgués Gasión, Jp, Busto Castañón, L, Caballero, Jm, Cabello Santamaría, F, Cabreja López, E, Carrasco Aznar, Jc, Casasola Chamorro, J, Castellanos González, L, Cimadevila García, A, Closas Capdevila, M, Concepción Masip, T, Conde, C, Conde Santos, G, Cortada i., Robert J, Cos Calvet, Jm, Crespi Martínez, F, Cruz, N, De la Rosa Khermann, M, Delgado Martín, Ja, Devesa Mújica, M, Doganis Peppas, C, Domínguez Freire, F, Donderis Guastavino, C, Duarte Vázquez, Jj, El Khoury Yacob, R, Escobal Tamayo, V, Farré Martí, Jm, Fernández Fernández, A, Fernández Lozano, A, Fernández Viñas, Ja, Fiter Gómez, L, Fleitas Asencio, E, Frago Valls, Sm, Galiana Álvarez, A, García Bayo, I, García Contreras, J, García Cruz, E, García de Jalón Martín, A, García Giralda, L, García Marco, Ma, García Navas, R, García Reboll, L, Garrido Insúa, S, Giner Santamaría, C, Gómez Berjón, F, Gómez Gil, E, Gómez Lanza, E, Gómez Pérez, L, Gómez Rodríguez, A, González Sala, Jl, González Sala, Mj, Gonzalvo Ybarra, A, Guerrero Martínez, V, Gutiérrez González, Ma, Gutierrez Mínguez, E, Hidalgo Arroyo, J, Hmeidan, M, Idígora i., Planas X, Jara Rascón, J, Jiménez Verdejo, J, Lledó García, E, Lliteras Arañi, M, López Almansa, M, López Palacios, Má, López Tello, J, Lorenzo Gómez, Mf, Luque Gálvez, P, Luque López, Aj, Mallafré Sala, Jm, Martí Cebrián, Jm, Martín Clos, J, Martín Huescar, A, Martín Morales, A, Martín Rodríguez, A, Martínez Rodríguez, R, Martínez Salamanca, Ji, Mascarós Balaguer, E, Mejide Manresa, R, Molero Rodríguez, F, Molina Carranza, A, Moncada Iribarren, I, Montagud Moncho, Jb, Montesino Semper, M, Mosteiro Ponce, Ja, Mouaffak Tatari, N, Navarro Gil, Jm, Novás Castro, S, Ortiz del Corral, Ml, Ortiz Gamiz, A, Osca García, Jm, Padilla León, M, Palomino García, A, Pascual Mateo, C, Peinado Ibarra, F, Pérez Mestre, M, Portillo Martín, Ja, Poyato Galán, Jm, Prats de Puig, J, Prieto Castro, R, Puigvert Martínez, A, Quintana de la Rosa, Jl, Ramada Benlloch, Fj, Reyes Martínez, F, Rigabert, M, Ríos Espuny, Af, Robles Iniesta, A, Rodrigo Aliaga, M, Rodríguez Alba, Jl, Rodríguez Bethencourt, F, Rodríguez Jiménez, Fj, Rodríguez Leal, Da, Rodríguez Rubio, F, Rodríguez Tolrá, J, Rodríguez Vallejo, Jm, Romero Otero, J, Roselló Barbará, M, Rubio Briones, J, Ruíz Moriana, O, Sampol Company, J, San Martín Blanco, C, Sánchez Encinas, M, Sánchez Sánchez, F, Sancho Serrano, C, Santandreu Puifros, J, Santisteban González, M, Santos Ascarza Tabares, Jl, Sanz Lahoz, I, Sapiña Ortola, F, Sarquella Geli, J, Segarra Tomás, J, Soler Fernández, J, Tato Rodríguez, J, Tesedo Cubedo, J, Traid Sender, V, Valbuena Álvarez, R, Valverde Rubio, Jm, Varela Salgado, M, Vargas Rugeles, M, Vilches Cocovi, E, Virto Bajo, Fj, Andius, P, Anker Hansen, O, Arver, S, Bosson, P, Brattberg, A, Grenabo, L, Hanning, J, Hassler, L, Paradis, Aå, and Wang, E.

Subjects
Adult, Complementary Therapies, Male, medicine.medical_specialty, Benzylamines, Adolescent, Nausea, Urology, Naphthalenes, Dapoxetine Safety Cardiovascular events Syncope, Syncope, Cardiovascular events, Young Adult, Internal medicine, Premature ejaculation, medicine, 80 and over, Dapoxetine, Safety, Aged, Aged, 80 and over, Humans, Middle Aged, Premature Ejaculation, Prospective Studies, Serotonin Uptake Inhibitors, Adverse effect, Prospective cohort study, Sertraline, business.industry, Settore MED/24 - UROLOGIA, Incidence (epidemiology), syncope, Anesthesia, Observational study, medicine.symptom, business, Selective Serotonin Reuptake Inhibitors, medicine.drug, Cardiovascular events, Dapoxetine, Safety, Syncope
Abstract

Background Dapoxetine hydrochloride is a selective serotonin reuptake inhibitor and the first drug approved for the on-demand treatment of premature ejaculation (PE). Its safety was established in a thorough clinical development program. Objective To characterize the safety profile of dapoxetine in PE treatment and to report the incidence, severity, and type of adverse events. Design, setting, and participants We conducted a 12-wk, open-label, observational study with a 4-wk, postobservational contact. A total of 10 028 patients were enrolled, with 6712 patients (67.6%) treated with dapoxetine 30–60mg (group A)and 3316 (32.4%) treated with alternative care/nondapoxetine (group B). Interventions Treatment with dapoxetine or alternative care/nondapoxetine. Outcome measurements and statistical analysis Treatment-emergent adverse events (TEAEs) and concomitant therapy use during the 12-wk observational and the postobservational period were reported. Results and limitations The mean age for all patients was 40.5 yr. In group A, 93.0% of the patients were initially prescribed dapoxetine 30mg. Treatment options for group B patients included clomipramine, paroxetine, fluoxetine, sertraline, topical drugs, condoms, and behavioral counseling. Both treatment regimens were well tolerated. TEAEs were reported by 12.0% and 8.9% of group A and group B, respectively, with the highest incidence observed in patients aged >65 yr for group A (21.4%) and 30–39 yr (9.8%) for group B. The most commonly reported TEAEs were nausea, headache, and vertigo, with a higher incidence in group A (3.1%, 2.6%, and 1.0%, respectively) than in group B (oral drugs: 2.3%, 1.3%, and 0.9%, respectively). There were no cases of syncope in group A and one case in group B. A major limitation is that this was a nonrandomized, open-label, short-term study lacking efficacy data. Conclusions The results of this postmarketing observational study demonstrated that dapoxetine for treatment of PE has a good safety profile and low prevalence of TEAEs. Syncope and major cardiovascular adverse events were not reported. The high level of adherence by healthcare providers to the contraindications, special warnings, and precautions for dapoxetine minimizes the risk for its use in routine clinical practice. The current risk minimization measures for its identified and potential risks are effective.

Published
2014

43. Transcarotid Transcatheter Aortic Valve Replacement: Feasibility and Safety

Author

Mylotte, D., SUDRE, A., Teiger, E., Obadia, Jean-François, Lee, M., Spence, M., Khamis, H., Al Nooryani, A., Delhaye, C., Amr, G., Koussa, M., Debry, N., Piazza, N., Modine, T., Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Institut National de la Recherche Agronomique (INRA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hospices Civils de Lyon (HCL), Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université Claude Bernard Lyon 1 (UCBL), and Université de Lyon-Institut National de la Recherche Agronomique (INRA)

Subjects
[SDV]Life Sciences [q-bio]
Abstract

International audience; OBJECTIVES: The purpose of this study was to assess the feasibility and safety of transcarotid transcatheter aortic valve replacement (TAVR). BACKGROUND: Many candidates for TAVR have challenging vascular anatomy that precludes transfemoral access. Transcarotid arterial access may be an option for such patients. METHODS: The French Transcarotid TAVR Registry is a voluntary database that prospectively collected patient demographics, procedural characteristics, and clinical outcomes among patients undergoing transcarotid TAVR. Outcomes are reported according to the updated Valve Academic Research Consortium criteria. RESULTS: Among 96 patients undergoing transcarotid TAVR at 3 French sites (2009 to 2013), the mean age and Society of Thoracic Surgeons predicted risk of mortality were 79.4 +/- 9.2 years and 7.1 +/- 4.1%, respectively. Successful carotid artery access was achieved in all patients. The Medtronic CoreValve (Medtronic, Inc., Minneapolis, Minnesota) (n = 89; 92.7%) and Edwards SAPIEN valves (Edwards Lifesciences, Irvine, California) (n = 7; 7.3%) were used. Procedural complications included: valve embolization (3.1%), requirement for a second valve (3.1%), and tamponade (4.2%). There were no major bleeds or major vascular complications related to the access site. There were 3 (3.1%) procedural deaths and 6 (6.3%) deaths at 30 days. The 1-year mortality rate was 16.7%. There were 3 (3.1%) cases of Valve Academic Research Consortium-defined in-hospital stroke (n = 0) or transient ischemic attack (TIA) (n = 3). None of these patients achieved the criteria for stroke and none manifested new ischemic lesions on cerebral computed tomography or magnetic resonance imaging. At 30 days, a further 3 TIAs were observed, giving an overall stroke/TIA rate of 6.3%. CONCLUSIONS: Transcarotid vascular access for TAVR is feasible and is associated with encouraging short- and medium-term clinical outcomes. Prospective studies are required to ascertain if transcarotid TAVR yields equivalent results to other nonfemoral vascular access routes.

Published
2016
Full Text
View/download PDF

44. An Overview of Proteomics Tools for Understanding Plant Defense Against Pathogens

Author

Grandellis, Carolina, Vranych, Cecilia V., Ainel&eacute, Piazza, n, Garavaglia, Betiana S., Gottig, Natalia, and Ottado, Jorgelina

Subjects
Proteomics, Proteomics methods, Proteome, business.industry, fungi, food and beverages, General Medicine, Plants, Biology, Plant disease resistance, crops, Bioinformatics, Biotechnology, Post translational, Organ Specificity, agricultural production, Host-Pathogen Interactions, Protein processing, Plant defense against herbivory, Plant diseases, business, Protein Processing, Post-Translational, Disease Resistance, Plant Proteins
Abstract

Plant diseases are responsible for important losses in crops and cause serious impacts in agricultural production. In the last years, proteomics has been used to examine plant defense responses against pathogens. Such studies may be pioneer in the generation of crops with enhanced resistance. In this review, we focus on proteomics advances in the understanding of host and non-host resistance against pathogens.

Published
2016
Full Text
View/download PDF

45. TRANSCATHETER AORTIC VALVE IMPLANTATION IN QUÉBEC: 4 YEARS OF COMPREHENSIVE EVALUATION AND RELATION TO QUALITY INDICATORS

Author

Lambert, L., primary, Azzi, L., additional, Désy, F., additional, Potter, B., additional, Racine, N., additional, Beauchemin, J., additional, Noiseux, N., additional, Asgar, A., additional, Daneault, B., additional, de Varennes, B., additional, Dumont, E., additional, Ibrahim, R., additional, Lamarche, Y., additional, Martucci, G., additional, Palisaitis, D., additional, Piazza, N., additional, Rodés-Cabau, J., additional, Afilalo, J., additional, Carrier, M., additional, de Guise, M., additional, and Bogaty, P., additional

Published
2017
Full Text
View/download PDF

47. Transcatheter Aortic Valve Replacement in Europe Adoption Trends and Factors Influencing Device Utilization

Author

Mylotte D, Osnabrugge RLJ, Windecker S, Lefevre T, de Jaegere P, Jeger R, Wenaweser P, Maisano F, Moat N, Sondergaard L, Bosmans J, Teles RC, Martucci G, Manoharan G, Garcia E, Van Mieghem NM, Kappetein AP, Serruys PW, Lange R, Piazza N, Cardiothoracic Surgery, Cardiology, Mylotte, D, Osnabrugge, Rlj, Windecker, S, Lefevre, T, de Jaegere, P, Jeger, R, Wenaweser, P, Maisano, F, Moat, N, Sondergaard, L, Bosmans, J, Teles, Rc, Martucci, G, Manoharan, G, Garcia, E, Van Mieghem, Nm, Kappetein, Ap, Serruys, Pw, Lange, R, and Piazza, N

Subjects
aortic stenosis, transcatheter aortic valve replacement, transcatheter aortic valve implantation
Abstract

ObjectivesThe authors sought to examine the adoption of transcatheter aortic valve replacement (TAVR) in Western Europe and investigate factors that may influence the heterogeneous use of this therapy.BackgroundSince its commercialization in 2007, the number of TAVR procedures has grown exponentially.MethodsThe adoption of TAVR was investigated in 11 European countries: Germany, France, Italy, United Kingdom, Spain, the Netherlands, Switzerland, Belgium, Portugal, Denmark, and Ireland. Data were collected from 2 sources: 1) lead physicians submitted nation-specific registry data; and 2) an implantation-based TAVR market tracker. Economic indexes such as healthcare expenditure per capita, sources of healthcare funding, and reimbursement strategies were correlated to TAVR use. Furthermore, we assessed the extent to which TAVR has penetrated its potential patient population.ResultsBetween 2007 and 2011, 34,317 patients underwent TAVR. Considerable variation in TAVR use existed across nations. In 2011, the number of TAVR implants per million individuals ranged from 6.1 in Portugal to 88.7 in Germany (33 ± 25). The annual number of TAVR implants performed per center across nations also varied widely (range 10 to 89). The weighted average TAVR penetration rate was low: 17.9%. Significant correlation was found between TAVR use and healthcare spending per capita (r = 0.80; p = 0.005). TAVR-specific reimbursement systems were associated with higher TAVR use than restricted systems (698 ± 232 vs. 213 ± 112 implants/million individuals ≥75 years; p = 0.002).ConclusionsThe authors' findings indicate that TAVR is underutilized in high and prohibitive surgical risk patients with severe aortic stenosis. National economic indexes and reimbursement strategies are closely linked with TAVR use and help explain the inequitable adoption of this therapy.

Published
2013

48. Transcatheter aortic valve implantation in failed bioprosthetic surgical valves

Author

Dvir, D., Webb, J.G., Bleiziffer, S., Pasic, M., Waksman, R., Kodali, S., Barbanti, M., Latib, A., Schaefer, U., Rodes-Cabau, J., Treede, H., Piazza, N., Hildick-Smith, D., Himbert, D., Walther, T., Hengstenberg, C., Nissen, H., Bekeredjian, R., Presbitero, P., Ferrari, E., Segev, A., Weger, A. de, Windecker, S., Moat, N.E., Napodano, M., Wilbring, M., Cerillo, A.G., Brecker, S., Tchetche, D., Lefevre, T., Marco, F. de, Fiorina, C., Petronio, A.S., Teles, R.C., Testa, L., Laborde, J.C., Leon, M.B., Kornowski, R., Valve In Valve Int Data Registry, and Valve-in-Valve International Data Registry Investigators

Subjects
Aortic valve, Adult, Male, medicine.medical_specialty, Cardiac Catheterization, medicine.medical_treatment, Aortic Valve Insufficiency, Prosthesis Design, Interquartile range, Internal medicine, Aged, Aged, 80 and over, Aortic Valve, Aortic Valve Stenosis, Female, Heart Valve Prosthesis Implantation, Humans, Middle Aged, Prosthesis Failure, Registries, Survival Analysis, Treatment Outcome, Bioprosthesis, Medicine (all), medicine, 80 and over, Survival rate, Survival analysis, Cardiac catheterization, business.industry, Hazard ratio, Aortic Valve/surgery, Aortic Valve Insufficiency/surgery, Aortic Valve Stenosis/surgery, Heart Valve Prosthesis Implantation/methods, General Medicine, medicine.disease, Surgery, Stenosis, medicine.anatomical_structure, Aortic valve stenosis, Cardiology, business
Abstract

IMPORTANCE: Owing to a considerable shift toward bioprosthesis implantation rather than mechanical valves, it is expected that patients will increasingly present with degenerated bioprostheses in the next few years. Transcatheter aortic valve-in-valve implantation is a less invasive approach for patients with structural valve deterioration; however, a comprehensive evaluation of survival after the procedure has not yet been performed. OBJECTIVE: To determine the survival of patients after transcatheter valve-in-valve implantation inside failed surgical bioprosthetic valves. DESIGN, SETTING, AND PARTICIPANTS: Correlates for survival were evaluated using a multinational valve-in-valve registry that included 459 patients with degenerated bioprosthetic valves undergoing valve-in-valve implantation between 2007 and May 2013 in 55 centers (mean age, 77.6 [SD, 9.8] years; 56% men; median Society of Thoracic Surgeons mortality prediction score, 9.8% [interquartile range, 7.7%-16%]). Surgical valves were classified as small (≤21 mm; 29.7%), intermediate (>21 and

Published
2014
Full Text
View/download PDF

49. PATIENT-LEVEL PREDICTORS OF BLEEDING IN OLDER ADULTS UNDERGOING TRANSCATHETER OR SURGICAL AORTIC VALVE REPLACEMENT

Author

Bendayan, M., primary, Lauck, S., additional, Kim, D., additional, Lefèvre, T., additional, Piazza, N., additional, Lachapelle, K., additional, Martucci, G., additional, Lamy, A., additional, Labinaz, M., additional, Peterson, M., additional, Aroroa, R., additional, Noiseux, N., additional, Rassi, A., additional, Genereux, P., additional, Lindman, B., additional, Asgar, A., additional, Trnkus, A., additional, Morais, J., additional, Langlois, Y., additional, Morin, J., additional, Rudski, L., additional, Pompa, J., additional, Webb, J., additional, Perrault, L., additional, and Afilalo, J., additional

Published
2016
Full Text
View/download PDF

50. DEPRESSION AS A PREDICTOR OF ALL-CAUSE MORTALITY IN OLDER ADULTS UNDERGOING TRANSCATHETER OR SURGICAL AORTIC VALVE REPLACEMENT

Author

Drudi, L., primary, Lauck, S., additional, Kim, D., additional, Lefèvre, T., additional, Piazza, N., additional, Lachapelle, K., additional, Martucci, G., additional, Lamy, A., additional, Labinaz, M., additional, Peterson, M., additional, Arora, R., additional, Noiseux, N., additional, Rassi, A., additional, Genereux, P., additional, Lindman, B., additional, Asgar, A., additional, Kim, C., additional, Morais, J., additional, Langlois, Y., additional, Morin, J., additional, Rudski, L., additional, Popma, J., additional, Webb, J., additional, Perrault, L., additional, and Afilalo, J., additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results